Van Honacker Eveline, Vandendriessche S, Coorevits L, Verhasselt B, Boelens J
Department of Medical Microbiology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
Department of Diagnostic Sciences, Ghent University, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
Eur J Clin Microbiol Infect Dis. 2022 Feb;41(2):203-207. doi: 10.1007/s10096-021-04364-6. Epub 2021 Oct 15.
On the first of January 2019, the European Committee on Antimicrobial Susceptibility Testing, EUCAST, introduced the concept of "area of technical uncertainty" (ATU). The aim was to report on the incidence of ATU test results in a selection of common bacterial species and the subsequent impact on antimicrobial resistance categorization and workload. A retrospective analysis of clinical samples collected from February 2019 until November 2019 was performed. Susceptibility to amoxicillin-clavulanic acid and piperacillin-tazobactam in Enterobacterales (Escherichia spp., Klebsiella spp., Proteus spp.), piperacillin-tazobactam in Pseudomonas aeruginosa, and amoxicillin-clavulanic acid and cefuroxime in Haemophilus influenzae was studied. Disk diffusion antibiotic susceptibility testing was read and interpreted by ADAGIO 93400 automated system (Bio-Rad, France). In case of an inhibition zone in the ATU, strains were retested using gradient minimal inhibitory concentration method (Etest, BioMérieux, France). Overall, 14,164 isolate-antibiotic combinations were tested in 7922 isolates, resulting in 1204 (8.5%) disk zone diameters in the ATU region. Retesting of ATUs with Etest resulted in a category change from S to R for amoxicillin-clavulanic acid in 63/498 (12.7%) of Escherichia spp., 2/58 (3.4%) of Klebsiella spp., 2/37 (5.4%) of Proteus spp., and 6/125 (4.8%) of Haemophilus influenzae. For piperacillin-tazobactam, a category change from S to R was found in 33/92 (35.9%) of Pseudomonas aeruginosa. We conclude that ATU testing has a substantial impact on the correct interpretation of antimicrobial resistance, at the expense of turn-around time and with the cost of additional workload.
2019年1月1日,欧洲抗菌药物敏感性试验委员会(EUCAST)引入了“技术不确定区域”(ATU)的概念。其目的是报告在选定的常见细菌物种中ATU检测结果的发生率,以及随后对抗菌药物耐药性分类和工作量的影响。对2019年2月至2019年11月期间收集的临床样本进行了回顾性分析。研究了肠杆菌科细菌(大肠埃希菌属、克雷伯菌属、变形杆菌属)对阿莫西林-克拉维酸和哌拉西林-他唑巴坦的敏感性,铜绿假单胞菌对哌拉西林-他唑巴坦的敏感性,以及流感嗜血杆菌对阿莫西林-克拉维酸和头孢呋辛的敏感性。采用ADAGIO 93400自动化系统(法国伯乐公司)读取和解释纸片扩散法抗生素敏感性试验结果。如果在ATU区域出现抑菌圈,则使用梯度最小抑菌浓度法(法国生物梅里埃公司的Etest)对菌株进行重新检测。总体而言,对7922株分离菌进行了14164种分离菌-抗生素组合的检测,结果显示在ATU区域有1204个(8.5%)纸片抑菌圈直径。用Etest对ATU进行重新检测后发现,大肠埃希菌属中63/498(12.7%)、克雷伯菌属中2/58(3.4%)、变形杆菌属中2/37(5.4%)以及流感嗜血杆菌中6/125(4.8%)的阿莫西林-克拉维酸耐药类别从敏感变为耐药。对于哌拉西林-他唑巴坦,铜绿假单胞菌中有33/92(35.9%)的耐药类别从敏感变为耐药。我们得出结论,ATU检测对抗菌药物耐药性的正确解读有重大影响,但代价是周转时间延长和增加额外工作量的成本。